Pharma & Biotech Global Week in Review 16 Nov 2011 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

 

Highlights this week included:

Codiovan (Valsartan / Hydrochlorothiazide) – Germany: Düsseldorf Valsartan/HTC proceedings referred to CJEU for preliminary ruling (The SPC Blog) (EPLAW)

Cotareg (Valsartan / Hydrochlorothiazide) – Italy: Court of Rome endorses the “infringement test” in a case concerning Novartis combination SPC (Kluwer Patent Blog) (The SPC Blog)

The Mad Hatter in Wonderland: South Africa’s new TK Bill (IP Watch)

 

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

 

General

Medicines Patent Pool responds to critics of Gilead licence (IP Watch)

Global action to open generic competition for key AIDS drug (IP Watch)

WHO Consultative Expert Working Group on R&D Financing holds open briefing on 18 November 2011 @ 5 PM in Salle C, WHO (KEI)

Let the experiment begin: Impact of ECJ stem cell ruling on synthetic blood development (Patent Docs)

More on de-linking IP from exclusivity (ipwars.com)

India: Pages from history: The mysterious legislative history of Section 3(d) (Spicy IP)

South Africa: The Mad Hatter in Wonderland: South Africa’s new TK Bill (IP Watch)

UK: Human protein had enough of an industrial application to be patented, says Supreme Court in Human Genome Sciences v Eli Lilly (Out-Law)

US: USPTO Guidance already bans patents on human organisms (Pharma Patents)

US: Will the Hatch-Waxman lock be sprung in 2012? (FDA Law Blog)

US: Patent settlement agreements remain in the spotlight, but not the unified spotlight the FTC might want (FDA Law Blog)

US: Senators introduce bill to encourage development of new antibiotics – Generating Antibiotic Incentives Now Act of 2011 (Patent Docs)

US: Congressional Budget Office: Generics bill would save US $4.8 billion (IP Watch)

US: BIO’s Prometheus v. Mayo amicus brief filed (BIOtechNOW)

 

Products

Alendronic acid – Switzerland: Patentability of invention not excluded where only feature of patent claim not comprised in the state of the art is a dosage regime (Kluwer Patent Blog)

Asacol (Mesalamine) –US: Warner Chilcott files patent infringement complaint against Zydus in reponse to Para IV certification (Patent Docs)

Codiovan (Valsartan / Hydrochlorothiazide) – Germany: Düsseldorf Valsartan/HTC proceedings referred to CJEU for preliminary ruling (The SPC Blog) (EPLAW)

Cotareg (Valsartan / Hydrochlorothiazide) – Italy: Court of Rome endorses the “infringement test” in a case concerning Novartis combination SPC (Kluwer Patent Blog) (The SPC Blog)

Delsym (Dextromethorphan polistirex) – US: Reckitt Benckiser files patent infringement complaint against Amneal following Para IV certification (Patent Docs)

Detrol (Tolterodine Tartrate) – US: New Jersey District Court Says ANDA approval delay and patent uncertainty are insufficient to support DJ jurisdiction in generic DETROL LA litigation (FDA Law Blog)

Exelon (Rivastigmine tartrate) – US: Novartis files patent infringement complaints against Actavis South Atlantic and Watson Lab’s in SD Florida and Delaware in reponse to Para IV certification filing (Patent Docs)

Fentora (Fentanyl citrate buccal) – US: Cephalon files patent infringement complaint against Mylan following Para IV certification (Patent Docs)

Focalin XR (Dexmethylphenidate hydrochloride) – US: Akermes Pharma Ireland files patent infringement suit against Actavis in response to Para IV challenge (Patent Docs)

Focalin XR (Dexmethylphenidate hydrochloride) – US: Celgene files patent infringement suit against Actavis South Atlantic in response to Para IV challenge (Patent Docs)

Glivec (Imatinib mesylate) – India: Glivec patent dispute: the case so far (Part III) (Patent Circle)

Nexavar (Sorafenib) – India: Bayer challenges “prima facie” determination in compulsory licensing case (Spicy IP)

Oracea (Doxycycline) – US: Galderma files patent infringement complaint against Amneal Pharmaceuticals in response to Para IV certification filing (Patent Docs)

Recombinant human erythropoetin – US: ITC issues opinion in Certain Products and Pharmaceutical Compositions Containing Recombinant Human Erythropoetin (337-TA-568) (ITC 337 Law Blog)

Seroxat (Paroxetine) – UK enters the fray on pay for delay (IP Whiteboard)

Simcor (Niacin, Simvastatin) – US: Abbott files patent infringement complaint against Sandoz in response to Para IV challenge (Patent Docs)

Tecovirimat – US: How the US government subsidized Ron Perelman’s smallpox drug: ST-246 (Tecovirimat) (KEI)

Tylenol – US: Fighting the retroactive elimination of false marking claims: Public Patent Foundation v McNeil-PPC (Patently-O)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: